Maxime Verhoeven

Published in Ann Rheum Dis. 2019;78:1333-1338 M.M.A. Verhoeven 1 M.J.H. de Hair 1 J. Tekstra 1 J.W.J. Bijlsma 1 J.M. van Laar 1 A. Pethö-Schramm 2 M.E.A. Borm 3 E.J. ter Borg 4 S.P. Linn-Rasker 5 X.M. Teitsma 1 F.P.J.G. Lafeber 1 J.W.G. Jacobs 1 P.M.J. Welsing 1 1 Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, the Netherlands; 2 F. Hoffmann-La Roche, Basel, Switzerland; 3 Roche Nederland BV, Woerden, the Netherlands; 4 Department of Rheumatology, Sint Antonius Ziekenhuis, Nieuwegein, the Netherlands; 5 Department of Rheumatology, Meander Medisch Centrum, Amersfoort, the Netherlands. Chapter 3: Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone withinstep- up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early andCAMERA-II treat-to-target trials.